GLPG1790 decreased the phosphorylation/activation levels of EphA2 and affected CRC cell viability and proliferation, inducing the promotion of cell-cycle arrest in the G1/S phase of the cell cycle. Here, EPHA2 is linked to colorectal carcinoma.